Literature DB >> 17199111

Defining target antigens for CD25+ FOXP3 + IFN-gamma- regulatory T cells in chronic hepatitis C virus infection.

Shuo Li1, Kathryn L Jones, David J Woollard, James Dromey, Geza Paukovics, Magdalena Plebanski, Eric J Gowans.   

Abstract

The mechanism behind the apparent lack of effective antiviral immune responses in chronic hepatitis C virus (HCV) patients is poorly understood. It remains unclear if natural regulatory T cells (Treg) contribute to the induction and maintenance of HCV persistence. We herein report for the first time that CD25(high)IFN-gamma(-)FOXP3(high) Tregs can be rapidly induced by culturing peripheral blood mononuclear cells (PBMCs) of HCV-positive patients with HCV protein-derived peptides. The HCV-specific Tregs, generally CD4(+)CD45RO(+), did not proliferate in response to HCV peptide and failed to produce interferon (IFN)-gamma, in distinct contrast to antiviral effector cells. Stimulation of healthy donor PBMCs with HCV peptides did not result in CD25 and FOXP3 upregulation above non-antigen background. To further investigate the antigen specificity of these potentially disease-associated natural Tregs, CD25(+) cells were isolated from PBMCs, labeled with carboxyfluorescein diacetate succinimidylester and added back to CD25-depleted PBMCs, and the co-cultures were then stimulated with individual peptides derived from the HCV core protein. We found that the actual peptide that can stimulate Treg varied between patients, but within any given subject only a small number of the peptides were able to stimulate Treg, suggesting the existence of dominant Treg epitopes. Although functional experiments for these peptides are ongoing in our laboratory, data presented here suggests that HCV-specific natural Tregs are abundant in infected individuals, in contrast to the extremely low frequency of anti-HCV effector T cells, supporting the view that natural Treg may be implicated in host immune tolerance during HCV infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17199111     DOI: 10.1038/sj.icb.7100020

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  26 in total

Review 1.  Natural regulatory T cells and persistent viral infection.

Authors:  Shuo Li; Eric J Gowans; Claire Chougnet; Magdalena Plebanski; Ulf Dittmer
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

2.  Level, phenotype and activation status of CD4+FoxP3+ regulatory T cells in patients chronically infected with human immunodeficiency virus and/or hepatitis C virus.

Authors:  N I Rallón; M López; V Soriano; J García-Samaniego; M Romero; P Labarga; P García-Gasco; J González-Lahoz; J M Benito
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

Review 3.  Regulatory T cells in viral hepatitis.

Authors:  Eva Billerbeck; Tobias Bottler; Robert Thimme
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

Review 4.  Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection.

Authors:  Christoph Neumann-Haefelin; Hans-Christian Spangenberg; Hubert-E Blum; Robert Thimme
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

Review 5.  The Immune Fulcrum: Regulatory T Cells Tip the Balance Between Pro- and Anti-inflammatory Outcomes upon Infection.

Authors:  Laura E Richert-Spuhler; Jennifer M Lund
Journal:  Prog Mol Biol Transl Sci       Date:  2015-08-18       Impact factor: 3.622

6.  Development of virus-specific CD4+ and CD8+ regulatory T cells induced by human herpesvirus 6 infection.

Authors:  Fang Wang; Jing Chi; Guangyong Peng; Feng Zhou; Jinfeng Wang; Lingyun Li; Dongju Feng; Fangyi Xie; Bin Gu; Jian Qin; Yun Chen; Kun Yao
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

7.  CD4+ T-cell engagement by both wild-type and variant HCV peptides modulates the conversion of viral clearing helper T cells to Tregs.

Authors:  Matthew F Cusick; Jane E Libbey; Joan Cox Gill; Robert S Fujinami; David D Eckels
Journal:  Future Virol       Date:  2013-07       Impact factor: 1.831

8.  Effects of combined traditional Chinese medicine with immunosuppressive agents for patients with myasthenia gravis.

Authors:  Guoyan Qi; Shanshan Gu; Peng Liu; Hongxia Yang; Huimin Dong
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 9.  Molecular and contextual markers of hepatitis C virus and drug abuse.

Authors:  Paul Shapshak; Charurut Somboonwit; Lydia N Drumright; Simon D W Frost; Deborah Commins; Timothy L Tellinghuisen; William K Scott; Robert Duncan; Clyde McCoy; J Bryan Page; Brian Giunta; Francisco Fernandez; Elyse Singer; Andrew Levine; Alireza Minagar; Oluwadayo Oluwadara; Taiwo Kotila; Francesco Chiappelli; John T Sinnott
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

10.  Analysis of FOXP3+ regulatory T cells that display apparent viral antigen specificity during chronic hepatitis C virus infection.

Authors:  Shuo Li; Stefan Floess; Alf Hamann; Silvana Gaudieri; Andrew Lucas; Margaret Hellard; Stuart Roberts; Geza Paukovic; Magdalena Plebanski; Bruce E Loveland; Campbell Aitken; Simon Barry; Louis Schofield; Eric J Gowans
Journal:  PLoS Pathog       Date:  2009-12-24       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.